 |
|
June 17, 2010
Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC) more »
December 17, 2009
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM) more »
December 15, 2009
Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42 more »
August 27, 2009
Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway more »
July 23, 2009
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome more »
May 27, 2009
Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting more »
May 11, 2009
FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway more »
May 4, 2009
Arno Therapeutics to Deregister its Common Stock under the Exchange Act more »
March 31, 2009
Arno Therapeutics Reports 2008 Year-End Financial Results more »
March 17, 2009
FDA Accepts IND for Arno Therapeutics’ Pan-DAC/Akt Inhibitor, AR-42 more »
November 14, 2008
Arno Therapeutics Announces Third Quarter 2008 Financial Results more »
November 3, 2008
Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference more »
October 30, 2008
Arno Therapeutics Appoints William F. Hamilton to Board of Directors more »
September 3, 2008
Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director more »
August 18, 2008
Arno Therapeutics Announces Second Quarter 2008 Financial Results more »
August 14, 2008
Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer more »
July 17, 2008
Arno Therapeutics Announces New Ticker Symbol more »
June 5, 2008
BioWorld Today - Arno Gets $18M Plus Market Access in Reverse Merger more »
June 4, 2008
Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger more »
Jan. 28, 2008
Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds more » |
